89bio to participate in the h.c. wainwright 25th annual global investment conference

San francisco, sept. 05, 2023 (globe newswire) -- 89bio, inc. (nasdaq: etnb), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the h.c. wainwright 25th annual global investment conference, being held in new york, ny on monday, september 11, 2023 at 7:00 am et.
ETNB Ratings Summary
ETNB Quant Ranking